TEST:

Labcorp® Plasma Complete™

ABL1 (ABL proto-oncogene 1), ABL2 (ABL Proto-Oncogene 2, Non-Receptor Tyrosine Kinase), AKT1 (V-akt murine thymoma viral oncogene homolog 1), AKT2 (V-akt murine thymoma viral oncogene homolog 2), AKT3 (V-akt murine thymoma viral oncogene homolog 3), ALK (Anaplastic lymphoma kinase), AR (Androgen receptor), ARAF (A-Raf Proto-Oncogene), ARID1A (AT-rich interaction domain 1A), ARID1B (AT-Rich Interaction Domain 1B), ARID2 (AT-Rich Interaction Domain 2), ASXL1 (ASXL Transcriptional Regulator 1), ATM (ATM serine/threonine kinase), BAX (BCL2-associated X protein), BCL2 (B-cell CLL/lymphoma 2), BCL2L1 (BCL2-like 1), BCL6 (B-cell CLL/lymphoma 6), BIRC3 (Baculoviral IAP repeat containing 3), BIRC5 (Baculoviral IAP repeat containing 5), BRAF (B-raf proto-oncogene), BRCA1 (Breast cancer 1, early onset), BRCA2 (Breast cancer 2, early onset), BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1), CCND1 (Cyclin D1), CCND2 (Cyclin D2), CCND3 (Cyclin D3), CD22 (CD22 Molecule), CD276 (CD276 Molecule), CDK2 (Cyclin-dependent kinase 2), CDK4 (Cyclin-dependent kinase 4), CDK6 (Cyclin-dependent kinase 6), CEBPA (CCAAT Enhancer Binding Protein Alpha), CHEK1 (Checkpoint kinase 1), CHEK2 (Checkpoint kinase 2), EGFR (Epidermal growth factor receptor), ELF3 (E74 Like ETS Transcription Factor 3), EPCAM (Epithelial cell adhesion molecule), ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3), ERBB4 (erb-b2 receptor tyrosine kinase 4), ERCC1 (Excision repair cross-complementation group 1), ERCC2 (Excision repair cross-complementation group 2), ERCC5 (ERCC Excision Repair 5 Endonuclease 2), FGFR1 (Fibroblast growth factor receptor 1), FGFR2 (Fibroblast growth factor receptor 2), FGFR3 (Fibroblast growth factor receptor 3), FLT1 (Fms-related tyrosine kinase 1), FOXO1 (Forkhead box O1), GATA1 (GATA Binding Protein 1), GATA2 (GATA Binding Protein 2), GATA3 (GATA binding protein 3), GNAQ (G Protein Subunit Alpha Q), HDAC1 (Histone Deacetylase 1), HDAC2 (Histone deacetylase 2), HER-2 (Human epidermal growth factor receptor 2), HLA-A (Major Histocompatibility Complex, Class I, A), HRAS (Harvey rat sarcoma viral oncogene homolog), IDH1 (Isocitrate dehydrogenase (NADP(+)) 1), IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2), IGF1R (Insulin-like growth factor 1 receptor), IGF2R (Insulin Like Growth Factor 2 Receptor), JAK1 (Janus Kinase 1), JAK2 (Janus kinase 2), JAK3 (Janus Kinase 3), KDM5C (Lysine Demethylase 5C), KEAP1 (Kelch Like ECH Associated Protein 1), KIT (KIT proto-oncogene, receptor tyrosine kinase), KMT2A (Lysine Methyltransferase 2A), MAP2K1 (Mitogen-activated protein kinase kinase 1), MAP2K2 (Mitogen-activated protein kinase kinase 2), MAP2K4 (Mitogen-Activated Protein Kinase Kinase 4), MAP3K1 (Mitogen-Activated Protein Kinase Kinase Kinase 1), MET (MET proto-oncogene, receptor tyrosine kinase), MLH1 (MutL homolog 1), MLH3 (MutL homolog 3), MSH2 (MutS Homolog 2), MSH3 (MutS Homolog 3), MSI (Microsatellite instability), NOTCH1 (Notch 1), NOTCH2 (Notch 2), NOTCH3 (Notch Receptor 3), PTCH1 (Patched 1), PTEN (Phosphatase and tensin homolog), RARA (Retinoic Acid Receptor Alpha), RHOA (Ras homolog family member A), SMAD2 (SMAD Family Member 2), SMAD3 (SMAD Family Member 3), SMAD4 (SMAD family member 4), TMB (Tumor Mutational Burden)